LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Mirati Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

-0.05% downside

Ziņu noskaņojums

By Acuity

34%

66%

95 / 380 Rangs Healthcare

Mirati Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūn. 14:31 UTC

Peļņas

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 19:36 UTC

Tirgus saruna

Oil Futures Post Solid Weekly Gains -- Market Talk

2025. g. 6. jūn. 19:28 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025. g. 6. jūn. 18:46 UTC

Tirgus saruna

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025. g. 6. jūn. 18:02 UTC

Tirgus saruna

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025. g. 6. jūn. 16:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:34 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:21 UTC

Tirgus saruna

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 6. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025. g. 6. jūn. 15:53 UTC

Tirgus saruna

Mexican Inflation Seen Rising in May -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 15:33 UTC

Tirgus saruna

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025. g. 6. jūn. 15:16 UTC

Tirgus saruna

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025. g. 6. jūn. 15:05 UTC

Tirgus saruna

Silver at its Highest In Nearly 15 Years -- Market Talk

2025. g. 6. jūn. 14:35 UTC

Tirgus saruna

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025. g. 6. jūn. 14:15 UTC

Tirgus saruna

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025. g. 6. jūn. 14:12 UTC

Peļņas

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025. g. 6. jūn. 14:09 UTC

Peļņas

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Mirati Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-0.05% uz leju

Prognoze 12 mēnešiem

Vidējais 58.67 USD  -0.05%

Augstākais 59 USD

Zemākais 58 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Mirati Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

0

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

95 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

EBITDA

Pamatdarbības peļņa

$

Par Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.